NCT04609930View on ClinicalTrials.gov

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Interventions
DRUG

Anti-PD-1 or anti-PD-L1

Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.

Trial Locations (1)

34295

UH Montpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT04609930 - Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation | Biotech Hunter | Biotech Hunter